Misonix Incorporated Attends International Meeting on Advanced Spine Techniques (IMAST) - Introduces New Product

FARMINGDALE, N.Y., July 18, 2012 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, has announced its participation in the 19th Annual IMAST Meeting, being held in Istanbul, Turkey, July 18-21, 2012, sponsored by the Scoliosis Research Society.

The Scoliosis Research Society, which is based in the United States, is an international organization dedicated to education, research and treatment of spinal deformities. Current membership includes more than 1,000 of the world’s leading spine surgeons, researchers, physician assistants and orthotists with approximately 700 of them expected to attend the IMAST Meeting. Sixty-five percent of the attendees are either orthopedic surgeons or neurosurgeons, with more than one-half coming from North America.

As an industry sponsor of IMAST, Misonix will be exhibiting and demonstrating its innovative BoneScalpel Ultrasonic Bone Cutting System, which is gaining acceptance with spine surgeons worldwide. At the meeting, the Company will be introducing its new 30mm Blade line extension, designed for precisely transecting larger bones and/or for providing deeper access into body cavities.

Consistent with the scientific theme of the meeting, significant numbers of scientific papers and posters will be presented, including a poster authored by Isador H. Lieberman, M.D., MBA, FRCSC, documenting his positive experiences using the BoneScalpel in 58 deformity surgeries. Dr. Lieberman is an orthopedic surgeon at the Scoliosis & Spine Tumor Center, Texas Back Institute and Texas Health Presbyterian Hospital in Plano, TX. Dr. Lieberman said, “The ultrasonic BoneScalpel allows me to perform a more precise and less traumatic osteotomy for my spinal deformity surgeries. I have used it in over 60 cases so far, and with each procedure I am learning more about its utility in enhancing the precision of spine surgery. It has become my standard tool for advanced bone dissections. Using the blade, I was able to revise a previous lumbar-thoracic fusion. What would have taken me 45-60 minutes per spinal level was completed in less than 10 minutes per level by using the BoneScalpel ultrasonic osteotome.”

The BoneScalpel is a novel ultrasonic osteotome used for safe, tissue-selective bone dissection that encourages en-bloc bone removal and refined osteotomies while sparing elastic soft tissue structures. Most users report that the surgical field is relatively bloodless and clean. Loss of viable bone is minimal and controllable. The BoneScalpel has been used extensively for bone removal in the cervical, thoracic and lumbar spine, including deformity surgery.

“We are excited about the opportunity to be part of this meeting of world renowned experts in advanced spinal deformity surgery,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. “We are privileged to demonstrate our state-of-the-art technology at this prestigious meeting, particularly in concert with Dr. Lieberman’s poster, which clearly depicts the clinical value associated with the Misonix BoneScalpel.”

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

SOURCE Misonix, Inc.